ProDa BioTech, LLC
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer (NCT06460298) | ProDa BioTech, LLC | 2024-08-20 |
| ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) (NCT06182072) | ProDa BioTech, LLC | 2023-09-14 |
| ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies (NCT05085548) | ProDa BioTech, LLC | 2021-10-29 |
Track ProDa BioTech, LLC automatically
Every clearance here is in the API, with alerts when new ones post.